Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2020
![](/report_cover/2671/burkholderia-pseudomallei-infections-pipeline-review-h2-2014_en.gif)
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections - Pipeline Review, H2 2020, provides an overview of the Burkholderia pseudomallei Infections (Infectious Disease) pipeline landscape.
Burkholderiapseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Burkholderia pseudomallei Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Burkholderia pseudomallei Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections - Pipeline Review, H2 2020, provides an overview of the Burkholderia pseudomallei Infections (Infectious Disease) pipeline landscape.
Burkholderiapseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Burkholderia pseudomallei Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Burkholderia pseudomallei Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burkholderia pseudomallei Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burkholderia pseudomallei Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burkholderia pseudomallei Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Burkholderia pseudomallei Infections (Melioidosis) - Overview
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development
Aradigm Corp (Inactive)
Entasis Therapeutics Holdings Inc
MerLion Pharmaceuticals Pte Ltd
Soligenix Inc
Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melioidosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGX-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products
Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones
Featured News & Press Releases
Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference
Jun 28, 2017: MerLion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin against Biological Threat Agents
May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis
Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Burkholderia pseudomallei Infections (Melioidosis) - Overview
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development
Aradigm Corp (Inactive)
Entasis Therapeutics Holdings Inc
MerLion Pharmaceuticals Pte Ltd
Soligenix Inc
Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melioidosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGX-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products
Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones
Featured News & Press Releases
Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference
Jun 28, 2017: MerLion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin against Biological Threat Agents
May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis
Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Aradigm Corp (Inactive), H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Entasis Therapeutics Holdings Inc, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H2 2020
Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Aradigm Corp (Inactive), H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Entasis Therapeutics Holdings Inc, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020